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Background—The generalizability of antiretroviral therapy (ART) clinical trial efficacy
findings to routine care settings is not well studied. We compared the relative effectiveness of
initial ART regimens estimated in AIDS Clinical Trial Group (ACTG) randomized controlled
trials with that among patients receiving ART at Antiretroviral Therapy Cohort Collaboration
(ART-CC) study sites.
Methods—Treatment-naive HIV-infected patients initiating identical ART regimens in ACTG
trials (A5095 and A5142) and at 15 ART-CC cohort study sites were included. Virological failure
(HIV-1 RNA >200 copies/ml) at 24- and 48-weeks, incident AIDS-defining events and mortality
were measured according to study design (ART-CC cohort vs. ACTG trial) and stratified by 3rd
drug [Abacavir (ABC), Efavirenz (EFV), and Lopinavir/r (LPV/r)]. We used logistic regression to
estimate and compare odds ratios for virological failure between different regimens and study
designs, and used Cox models to estimate and compare hazard ratios for AIDS and death.
Results—Compared with patients receiving ABC, those receiving EFV had roughly half the
odds of 24-week virologic failure (>200 copies/mL) in both ACTG 5095 (OR=0.53, 95% CI 0.36–
0.79) and ART-CC (0.46, 0.37–0.57). Virologic superiority of EFV (vs. ABC) appeared
comparable in ART-CC and ACTG 5095 (ratio of ORs 0.86, 95% CI 0.54–1.35). Odds ratios for
48-week virologic failure, comparing EFV with LPV/r, were also comparable in ACTG 5142 and
ART-CC (ratio of ORs 0.87, 0.45–1.69).
Conclusions—Between ART regimen virologic efficacy of 3rd drugs ABC, EFV, and LPV/r
observed in the ACTG 5095 and 5142 trials appear generalizable to the routine care setting of
ART-CC clinical cohorts.
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Introduction
Randomized controlled clinical trials are the cornerstone of evidence based medicine and are
essential to inform human immunodeficiency virus (HIV) antiretroviral treatment (ART)
guidelines and clinical practice decisions.1–3 For over two decades, the Adult AIDS Clinical
Trial Group (ACTG) has been a leading organization in the conduct of clinical trials,
including those comparing the efficacy of initial ART regimens-(https://actgnetwork.org/).
Because of the potential for selection bias imposed by trial eligibility criteria and volunteer
bias for participation in clinical trials, there is always uncertainty whether clinical trial
findings will be generalizable to the broader patient population treated through routine
clinical care outside the context of a study.4, 5 Regardless, randomized controlled trials
remain the optimal means to compare the efficacy between treatment strategies and the only
study methodology able to directly assess causality.
Observational cohort studies offer a complementary research design that allows for a
comparison of the effectiveness of different treatment strategies in routine care settings.
Analyses of HIV cohort studies have similarly made important contributions to treatment
strategies, particularly in assessing effects on clinical events and mortality, which often
cannot be adequately evaluated in clinical trials because of limited duration of RCTs and
low event frequency. The Antiretroviral Therapy Cohort Collaboration (ART-CC) has been
a leading, international multi-site HIV cohort study for over a decade
(http://www.art-cohort-collaboration.org).6, 7 A notable limitation inherent to cohort studies
is the potential for confounding by indication and unmeasured confounding, which may
impact outcome interpretation and reliability of study findings.4, 5, 8, 9 Regardless, well
conducted observational cohort studies play an important role in HIV treatment decisions as
Mugavero et al. Page 2













they are inclusive and reflective of treatment responses and outcomes of the broader
population of HIV-infected persons than typically studied through clinical trials and
generally can provide longer follow-up.
In recent years, considerable emphasis has been placed on the importance of comparative
effectiveness research (CER) to allow for informed treatment decisions to improve
individual and population level health.10 Inherent to the definition of CER is the direct
comparison of alternative treatments in patients typical of those treated in day-to-day
clinical care. Among the priority areas in the CER agenda is the development and evaluation
of methodologies of clinical research that address limitations of existing study designs to
generate novel data elements to augment the traditional evidence base thereby fostering
more informed treatment decisions.10 Here, we compare patient-level virologic and clinical
effectiveness of a number of initial ART regimens estimated in ACTG clinical trials with
that estimated in patients treated in routine clinical care and enrolled in cohorts participating
in the ART-CC. To our knowledge, this is the first large-scale regimen-level comparison of
contemporary initial ART regimens among patients receiving treatment through clinical
trials v. routine care. These analyses address the pivotal questions of whether ART efficacy
findings observed in clinical trials translate to routine care settings, and whether differential
ART regimen-level effects are observed across study designs and treatment settings.
Methods
Setting and Participants
AIDS Clinical Trial Group (ACTG) Study 5095—ACTG 5095 is a randomized,
double-blind study that compared three ART regimens for the initial treatment of subjects
infected with HIV-1 and has been described in detail.11, 12 We used data from the two arms
of the trial that compared three drug regimens: zidovudine (AZT), lamivudine (3TC) and
abacavir (ABC) with AZT+3TC plus efavirenz (EFV).
Eligible patients were HIV-1–infected adults who had received no previous ART and who
had a plasma HIV-1 RNA level of at least 400 copies/mL and acceptable safety laboratory
results across a range of different measures. Patients were excluded if they had received
immunomodulator or investigational therapy or vaccines within the previous 30 days, if they
weighed less than 40 kg, or if they were pregnant or breast-feeding. Subjects enrolled in the
study between March 2001 and November 2002.
ACTG Study 5142—ACTG 5142 is a randomized, open-label trial that compared three
ART regimens for the initial treatment of subjects infected with HIV-1 and has been
described in detail.13 We used data from the two arms of the trial that compared EFV with
lopinavir boosted with ritonavir (LPV/r) each together with two NRTIs (3TC with either
AZT or stavudine (D4T) or tenofovir (TDF)).
The study population consisted of HIV-1–infected patients at least 13 years of age who had
not received previous ART. All patients had a plasma HIV-1 RNA level of at least 2000
copies/mL with any CD4 cell count, and acceptable laboratory results across a range of
different measures. Patients were enrolled from January 2003 to May 2004.
ART-CC Cohort Collaboration (ART-CC)—ART-CC is an international collaboration
between the investigators of cohort studies of HIV-1–infected patients from Europe and
North America that was established in 2000 to estimate prognosis of HIV-1 infected,
treatment-naïve patients initiating combination ART. The collaboration has been described
in detail elsewhere.6, 7 Prospective cohort studies were eligible for participation if they had
enrolled at least 100 HIV-1–infected patients aged 16 years or more who had not previously
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received antiretroviral treatment, started ART with a combination of at least three
antiretroviral drugs after 1996, and been followed for a median duration of at least 1 year
after ART initiation. The dataset analyzed here was assembled during 2009 and included
data from 15 cohorts: the AIDS Therapy Evaluation Project, Netherlands (ATHENA),14 the
Agence Nationale de la Recherche sur le SIDA et les hépatites virales (ANRS) CO3
Aquitaine Cohort,15 the ANRS CO4 French Hospital Database on HIV (FHDH),16 the
Italian Cohort of Antiretroviral-Naive Patients (ICONA),17 the Köln/Bonn Cohort,
Germany,18 the Proyecto para la Informatización del Seguimiento Clínico-epidemiológico
de la Infección por HIV y SIDA (PISCIS) Cohort,19 Cohorte de la Red de Investigación en
Sida (CoRIS Cohort),20 VIH-Aplicación de Control Hospitalario (VACH) Cohort, Spain,
the Royal Free Hospital Cohort, UK,21 the British Columbia Center for Excellence in HIV
(HOMER),22 the South Alberta Cohort,23 Canada, the Swiss HIV Cohort Study (SHCS),24
the 1917 Clinic Cohort from the University of Alabama,25 the HIV Atlanta VA Cohort
Study (HAVACS)26 and the University of Washington HIV Cohort, US. At all sites,
institutional review boards approved the collection of data. All cohorts provided
anonymized data on a predefined set of demographic, laboratory, and clinical variables,
which were then pooled and analyzed centrally.
Patient selection
All patients enrolled in the specified arms of ACTG 5095 and in ACTG 5142 and who had
measurements of CD4 count and HIV-1 RNA at start of ART were included. Patients in
ART-CC included in this study initiated ART after 1 January 2000 and had at least one year
of follow-up before end of study. Comparator patients in ART-CC started on the same
regimens as in the corresponding trial: for ACTG 5095 EFV or ABC together with AZT
+3TC, and for ACTG 5142 EFV or LPV/r together with 3TC plus choice of AZT or D4T or
TDF. Our analysis included all subjects meeting our eligibility criteria from each study.
Formal matching according to ART regimen constituents was not done, as we did not
conduct a case-control study. Potential imbalances across study designs with respect to
regimen constituents were controlled for in multivariate analyses.”
Statistical analyses
In all analyses, we used an intent-to-continue-treatment approach, and thus ignored changes
to treatment regimen, including treatment interruptions and terminations. In ART-CC
baseline measurements of CD4 count and viral load were the nearest to date of starting ART
within 3 months before start date. Measurements at 24 and 48 weeks were the nearest within
a window of +/− 7 weeks. Primary analyses included patients with available HIV RNA
measures and patients with missing outcome data were excluded.
Comparison of ACTG 5095 and ART-CC—We defined virologic failure as a single
HIV-1 RNA level >200 copies/ml at 24 weeks. Because of early termination of the ABC
arm in A5095,12 24 week virologic failure was selected over 48-weeks as the primary
outcome measure. We used logistic regression to estimate crude and adjusted odds ratios
(ORs) for virological failure comparing EFV v. ABC as a third drug in both ACTG 5095
(“trial”) and ART-CC (“cohort”). Models were adjusted for year of starting ART, age, sex,
assumed transmission via injection drug use (IDU), prior AIDS diagnosis, CD4 count and
HIV RNA at start of ART. We estimated ratios of odds ratios (OR in cohort\OR in trial) to
compare relative effects of ART regimens in the cohort and trial settings; formal criteria for
these comparisons are not established. We also estimated the OR for virological failure
comparing trial with cohort, separately in patients on EFV and on ABC.
We used Cox proportional hazards models to estimate crude and adjusted hazard ratios (HR)
comparing the effect of ART regimens on the clinical endpoint of time to AIDS or death, in
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both the trial and the cohort. We estimated ratios of HR (HR in cohort\HR in trial) to
compare the relative effects of ART regimens in the cohort and trial settings. We estimated
HR for AIDS or death comparing the cohort with trial, within strata defined by drug
regimens. As there were few deaths in the trial, mortality HRs were only estimated using
cohort data (analysis stratified by constituent cohorts).
Comparison of ACTG 5142 and ART-CC—Analyses described above were repeated to
compare EFV with LPV/r as a third drug using data from ACTG 5142 and ART-CC. The
primary end point for these analyses was 48 week virological failure, defined as a single
HIV-1 RNA level >200 copies/ml. We also investigated progression to AIDS and death.
Sensitivity analyses—Analyses were repeated using a higher threshold for virological
failure (HIV-1 RNA > 400 copies/ml), which allowed the inclusion of additional patients
from ART-CC who had viral load measured using a less sensitive assay. We repeated all
analyses stratifying by baseline HIV-1 RNA (<100,000, ≥100,000 copies/mL) and CD4
count (<200, ≥200 cells/µL). Finally, we conducted sensitivity analyses using a 3-month
window around the 24- and 48-week endpoints and also conducted analyses carrying the last
viral load value forward to evaluate the potential impact of missing viral load measurements
using a +/− 7 week window.
Role of the Funding Source
This study was supported by the UK Medical Research Council and the US National
Institutes of Health, neither of which played a role in the study’s design, conduct, and
reporting.
Results
Patient characteristics are presented by third drug (ABC, EFV, and LPV/r) and study design
(Table 1); ACTG 5095 (n=753) and identical regimens in ART-CC (n=4610), and ACTG
5142 (n=498) and identical regimens in ART-CC (n=8212). In general, the proportion of
female patients was slightly higher for ART-CC than for ACTG, while median age at ART
initiation was similar (roughly 38 years) across arms and study designs. Median CD4 counts
at ART initiation were approximately 200 cells/µL in all ACTG treatment arms and among
those receiving EFV in ART-CC, with notable differences among ABC (median 250 cells/
µL) and LPV/r (median 146 cells/µL) treated patients in the ART-CC. Virologic failure
(>200 copies/mL) was higher among ABC treated patients in both ACTG 5095 and ART-
CC relative to EFV and LPV/r treated patients in A5095, A5142 and ART-CC. AIDS-
defining events and deaths were relatively infrequent at 48 weeks following ART initiation,
and notably higher among ART-CC patients.
Adjusted estimates of virologic effectiveness stratified by 3rd drug (Table 2), showed that
patients receiving EFV had roughly half the odds of 24-week virologic failure (>200 copies/
mL) compared with ABC treated patients for both ACTG 5095 (OR=0.53, 95% Confidence
Interval=0.36–0.79) and ART-CC (0.46, 0.37–0.57). The ratio of ORs (0.86, 0.54–1.35),
(cohort study effectiveness/clinical trial efficacy, or effectiveness/efficacy ratio), indicates
the virologic superiority of EFV v. ABC was comparable in ART-CC and ACTG 5095.
Adjusted estimates of 48-week virologic effectiveness showed that the odds of failure were
similar for EFV compared with LPV/r in ACTG 5142 (0.97, 0.51–1.85), but somewhat
lower for EFV compared with LPV/r in ART-CC (0.84, 0.71–1.00). However, the ratio of
ORs (0.87, 0.45–1.69) did not provide evidence that cohort effectiveness differed from trial
efficacy. Adjusted analyses comparing study design (ACTG 5095 v. ART-CC and A5142 v.
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ART-CC, Table 2), found comparable odds of virologic failure in trials compared with the
cohort study across all treatment regimens.
When comparing 48-week AIDS defining events or deaths stratified by 3rd drug (Table 3),
there was clear evidence of confounding by indication in estimates based on cohort data,
suggested by sizeable shifts in parameter estimates in adjusted analyses. Consistent with the
patterns of prognostic factors in the cohort data presented in Table 1, the effect of EFV
compared with ABC was more beneficial after adjustment, while the effect of EFV
compared with LPV was attenuated towards 1. Estimates from trials were imprecise because
of the small number of events. In adjusted analyses patients receiving EFV had lower rates
of AIDS and death compared with those receiving ABC in both ACTG 5095 (0.60, 0.26–
1.41) and ART-CC (0.73, 0.54–0.99). Rates of AIDS and death appeared similar in patients
treated with EFV and LPV/r in both ACTG 5142 (0.96, 0.40–2.30) and ART-CC (0.88,
0.73–1.06). Effectiveness estimated in ART-CC appeared similar to efficacy estimated in
ACTG trials for each regimen comparison (ratios of ORs EFV v. ABC; 1.21, 0.50–2.95 and
EFV v. LPV/r; 0.92, 0.39–2.17).
Adjusted analyses of all-cause 48-week mortality by ART regimen were restricted to
patients in ART-CC (because there were insufficient deaths in both ACTG 5095 and ACTG
5142). There was little evidence of between-regimen differences in mortality rates (EFV v.
ABC, 0.81, 0.48–1.38; EFV v. LPV/r 0.85, 0.63–1.15), although confidence intervals were
wide (Table 4).
Findings from sensitivity analyses using a virologic failure threshold of 400 copies/mL were
largely in accordance to those from primary analyses (Supplemental Digital Content
appendix 1). Analyses of virological failure stratified by viral load and CD4 count at ART
initiation showed that the benefit of EFV over ABC is greater in patients with viral load
≥100,000 (v. <100,000) copies/mL and in those with CD4 count <200 (v. ≥200) cells/µL
(Supplemental Digital Content appendix 2). Finally, at viral load ≥100,000 (v. <100,000)
copies/mL, more disparate findings in comparisons of EFV v. LPV/r stratified by study
design and cohort v. trial stratified by regimen are observed relative to primary analyses,
albeit with wide confidence intervals (Supplemental Digital Content appendix 2).
Discussion
Among patients initiating antiretroviral therapy for HIV infection, differences in virologic
and clinical effectiveness between ART regimens compared in the ACTG 5095 and ACTG
5142 were similar to observed differences when comparing identical regimens administered
in routine care in the ART Cohort Collaboration. The virologic superiority of EFV over
ABC observed in ACTG 5095 was similar to that seen in the ART-CC, suggesting the
findings of this trial translated well to a routine care setting. The comparable efficacy of
EFV and LPV/r as a third drug paired with 2 NRTIs in ACTG 5142 was mirrored by the
similar virological and clinical effectiveness of these regimens in ART-CC. To our
knowledge, this is the first large scale regimen level evaluation of the comparative
effectiveness of initial ART when administered in a clinical trial and routine care settings.
Our finding that ART regimen differences in the ACTG clinical trials correlated with the
routine care setting of ART-CC suggests the generalizability of the results and provides an
important link between clinical trials and their applicability to a broader patient population.
Although comparisons of clinical trial efficacy with routine care effectiveness are well
documented for other medical conditions,27–30 evaluation of ART regimens for the
treatment of HIV infection in clinical trials vs. routine clinical care has not been widely
studied.31, 32 A recent study from a single, academic US HIV clinic found similar rates of
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virologic suppression among patients receiving ART through clinical trials and routine care,
but could only assess treatment strategy (trial v. routine care) as the sample was too small
for regimen level comparisons.32 Because care providers must choose among numerous
initial ART regimen options, the ability of the current study to move beyond treatment
strategy to the regimen level should provide valuable information to inform HIV treatment
decisions in accordance with the goals of comparative effectiveness research.10 In the
current study, the clinical trial efficacy of evaluated regimens (EFV, ABC, and LPV/r paired
with 2 NRTIs) was mirrored by the effectiveness in routine care settings.
In the evaluation of virologic effectiveness, the definition of virologic failure and analytic
approach to assess failure in the current study differed from the primary analyses in the
original ACTG 5095 and 5142 studies.11–13 This is particularly noteworthy with regards to
the comparison of virologic effectiveness between EFV v. LPV/r. In the original ACTG
5142 study, EFV was found to have superior virologic efficacy relative to LPV/r using
survival methods and with assessment of virologic failure starting at 32-weeks following
ART start.13 Of note, as seen with the current analyses, similar rates of cross-sectional 48-
week virologic failure were observed between the EFV and LPV/r groups in original
analyses of the ACTG 5142 study, although at 96-weeks patients receiving EFV were
significantly more likely to achieve a viral load <200 c/mL (93% v. 86%, P=0.04).13 The
analytic approach employed for the current study, cross-sectional evaluation of unconfirmed
virologic failure (>200 copies/mL) at 48-weeks after ART start, was selected based on
availability of plasma HIV RNA measures in the ART-CC. In contrast to the ACTG studies,
plasma HIV RNA measures are obtained considerably less frequently in routine care,
making the definition and analytic methods employed in clinical trials impractical for cohort
data based on the limited availability of outcome measures.
Several strengths of our study are noteworthy. This study represents an initial collaboration
between the Adult ACTG and ART-CC to allow for innovative approaches to evaluate ART
regimen performance at the patient level. The evaluation of clinical events in additional to
virologic failure adds contextual richness to the between ART regimen comparisons and
provides important information for patients and providers. Beyond the evaluation of
between ART regimen differences in surrogate HIV biomarkers across study design,
evaluation of clinical events has important implications for patient health. The conduct of
sensitivity analyses, the results of which are largely in accordance with findings from
primary analyses (see web appendices), provides additional confidence in the interpretation
of study findings.
Our study has limitations. As with all observational studies, there is potential for
unmeasured confounding that may bias estimates from cohort data.4, 5 The imbalances in
prognostic factors between cohort patients who received different regimens were reflected in
differences between the crude and adjusted hazard ratios for clinical events presented in
Table 3. However, we cannot exclude the possibility that further, unmeasured prognostic
factors were used by physicians choosing between different ART regimens in routine care
settings. Many of the NRTIs evaluated in the current study are not among those
recommended in updated HIV treatment guidelines.1–3 Future analyses should assess more
modern ART regimens. ART-CC includes patients in Europe, Canada and the US, whereas
with the exception of a handful of individuals in A5142 enrolled in South Africa, ACTG
sites in these studies are restricted to the US and Puerto Rico. Analyses were conducted
according to intent-to-continue-treatment principles and ignoring missing outcome data as
done for the original ACTG clinical trials such that the impact of treatment changes,
terminations and missing data were not evaluated in the current analyses. On-going studies
in the ART-CC are evaluating ART interruptions, terminations and switches. Since patient
follow-up in ACTG studies continues beyond initial treatment change or failure, future
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analyses may be possible to evaluate these factors. At 24-weeks, missing viral load data was
observed in 7% of ACTG participants and 31% of ART-CC patients, which may impact
outcomes interpretation. However, missing viral load data was observed in 7% of ACTG
participants and 13% of ART-CC patients in sensitivity analyses using a 3-month window
around the 24-week endpoint. Sensitivity analyses using this wider viral load measurement
window as well as those using a last viral load carried forward approach yielded findings
consistent with primary analyses (Supplemental Digital Content appendix 3). Confidence
intervals were fairly wide, particularly for the ratio of odds and hazards ratios, limiting the
precision of parameter estimates. Although caution must be exercised when comparing
findings across studies and designs, we suggest our analyses have an important role and are
particularly germane in light of considerable recent emphasis on comparative effectiveness
research and methodology.10
In conclusion, our study found ART regimen virologic and clinical efficacy for ABC, EFV,
and LPV/r in combination with 2 NRTIs observed in ACTG 5095 and 5142 clinical trials
were mirrored when these regimens were administered in the routine care setting at ART-
CC clinical sites. The generalizability of findings for these trials to routine care settings
suggests ART regimen performance in clinical trials likely translates to routine care settings.
Although additional studies are needed to confirm our findings and evaluate other ART
regimens, we believe our study provides pivotal new evidence demonstrating the
comparative effectiveness of antiretroviral treatments evaluated in clinical trials and a large
clinical cohort study; this research will help inform ART treatment decisions for HIV-
infected patients in routine clinical care.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Adjusted odds ratio (OR) for virological failure (HIV-1 RNA >200 copies/ml) with ratio of
odds ratios at 24 and 48 weeks after starting treatment between study design comparison of
drug regimen (3rd drug) and between drug regimen comparison of study design (ACTG5095
EFV v. ABC, ACTG5142 EFV v.ABC).
1a) Odds ratio (OR) for virological failure at 24 (diamond) and 48 (square) weeks from start
of ART comparing efavirenz (EFV) with abacavir (ABC) within ACTG 5095 trial and ART-
CC cohorts (left panel) and comparing trial with cohort separately for patients on EFV and
on ABC (right panel) together with ratio of ORs. 1b) Odds ratio (OR) for virological failure
at 24 (diamond) and 48 (square) weeks from start of ART comparing efavirenz (EFV) with
lopinavir/r (LPV/r) within ACTG 5142 trial and ART-CC cohorts (left panel) and
comparing trial with cohort separately for patients on EFV and on LPV/r (right panel)
together with ratio of ORs. The comparable ratio of odds ratios suggest the between ART
regimen virologic efficacy of 3rd drugs ABC, EFV, and LPV/r observed in the ACTG 5095
and 5142 trials appear generalizable to the routine care setting of ART-CC clinical cohorts.
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